Patients with type 2 diabetes who have psoriasis show an increased risk for renal disease despite biologics and ...

BALTIMORE, April 16, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines ...

During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated ...

Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in ...

The study, part of a series, evaluates the effects of the company’s novel oral TNF-alpha inhibitor, isomyosamine, on preserving lean muscle mass amid weight loss treatments. With a market ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International ...

The study, part of a series, evaluates the effects of the company’s novel oral TNF-alpha inhibitor, isomyosamine, on preserving lean muscle mass amid weight loss treatments. With a market ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver ...